Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

esketamine

- PMLiVE

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase

- PMLiVE

J&J’s Jane Griffiths named global head of Actelion

Appointment will effect once Swiss biotech's acquisition is completed

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

Pfizer launches app to help patients manage depression

Hopes the Moodivator app will complement treatment and support care teams

- PMLiVE

GSK and J&J file sirukumab for rheumatoid arthritis in EU

If approved it will compete with Roche blockbuster Actemra

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m

- PMLiVE

J&J buys firm seeking hepatitis B cure

Acquires Philadelphia-based Novira therapeutics

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Sidestep into Crohn’s could help Stelara cope with new competition

Filing for new indication expected before year's end

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links